{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-013745","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2023-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.929807+00:00","generated_at":"2026-06-16T21:06:44.441708+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Plus Therapeutics stockholders approve reverse stock split authorization at annual meeting","bullets":["Reverse stock split approved; ratio of 1:3 to 1:15 to be set by board at a later date.","All six director nominees elected, including Marc Hedrick and Howard Clowes.","BDO USA ratified as independent auditor for 2023; say-on-pay passed with 4.58M for.","Stockholders favored one-year frequency for future advisory votes on executive compensation.","Amended 2020 Stock Incentive Plan approved; preferred stock (50M votes) voted proportionally on split."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-013745","json":"https://secwatch.observer/filing/0000950170-23-013745.json","markdown":"https://secwatch.observer/filing/0000950170-23-013745.md","text":"https://secwatch.observer/filing/0000950170-23-013745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/pstv-20230420.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T21:06:44.441708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51392be3aa92046937f1496eb629aecb4c7df02a","claim":"PLUS THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on the compensation of the Company’s named executive officers at the 2023-04-20 meeting.","evidence_excerpt":"3. Proposal to provide a non-binding advisory vote on the compensation of the Company’s named executive officers: For Against Abstain 4,580,421 1,735,989 179,468","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-20"}],"fact_type":"shareholder_vote"},{"claim_id":"7f1c36e97a73272ca8cf187aca689ac03a06ae10","claim":"PLUS THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a ratio of not less than 1-for-3 and not greater than 1-for-15 at the 2023-04-20 meeting.","evidence_excerpt":"5. Proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-three (1:3) to one-for-fifteen (1:15): For Against Abstain 52,798,957 12,179,757 517,698","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-20"}],"fact_type":"shareholder_vote"},{"claim_id":"80dc72b72fa8470986f83365f2d7e3f94cff5251","claim":"PLUS THERAPEUTICS, INC. shareholders approved Election of six directors to serve until the 2024 annual meeting or until their successors are duly elected and qualified at the 2023-04-20 meeting.","evidence_excerpt":"1. Proposal to elect six directors to serve until the 2024 annual meeting or until their successors are duly elected and qualified: For Withheld Broker Non-Votes Howard Clowes 5,306,629 1,189,249 9,000,533 An van Es-Johansson 5,387,484 1,108,394 9,000,533 Richard J. Hawkins 5,364,397 1,131,481 9,000,533 Marc H. Hedrick, M.D. 5,700,185 795,693 9,000,533 Robert Lenk 5,308,285 1,187,593 9,000,533 Greg Petersen 5,675,200 820,678 9,000,533","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-20"}],"fact_type":"shareholder_vote"},{"claim_id":"bb1360b02e52bdc07a9c891320cce17556785e40","claim":"PLUS THERAPEUTICS, INC. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent auditors for the 2023 fiscal year at the 2023-04-20 meeting.","evidence_excerpt":"2. Proposal to ratify the appointment of BDO USA, LLP as the Company’s independent auditors for the 2023 fiscal year: For Against Abstain 14,681,590 617,972 196,849","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-20"}],"fact_type":"shareholder_vote"},{"claim_id":"e6b2690774f1a4f57b46fb84ef8ff90c347efcd5","claim":"PLUS THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation at the 2023-04-20 meeting.","evidence_excerpt":"4. Proposal to provide a non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation: One Year Two Years Three Years Abstain 5,695,824 105,972 401,874 292,208","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-20"}],"fact_type":"shareholder_vote"},{"claim_id":"fb23d784a9d1eef8096af788116fb560ff04922e","claim":"PLUS THERAPEUTICS, INC. shareholders approved Approval of the third amendment and restatement of the Company’s 2020 Stock Incentive Plan at the 2023-04-20 meeting.","evidence_excerpt":"6. Proposal to approve the third amendment and restatement of the Company’s 2020 Stock Incentive Plan: For Against Abstain 4,279,475 2,112,637 103,766","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-20"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}